[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542683":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":35,"centralContacts":42,"locations":48,"responsibleParty":64,"collaborators":30,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":30,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":51,"whyStopped":30,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"KU Leuven","OTHER",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Gastro-esophageal cancer group","EXPERIMENTAL","Participants with gastroesophageal cancer providing a breath and blood sample for biomarker identification",[13,14],"Diagnostic Test: Breath analysis","Diagnostic Test: Blood analysis",{"label":16,"type":17,"description":18,"interventionNames":19},"Barrett's esophagus group","ACTIVE_COMPARATOR","Participants with Barrett's esophagus providing a breath and blood sample for biomarker identification",[13,14],{"label":21,"type":17,"description":22,"interventionNames":23},"Healthy controls","Healthy controls providing a breath and blood sample for biomarker identification",[13,14],[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DIAGNOSTIC_TEST","Breath analysis","Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath",[16,9,21],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Blood analysis","Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood",[16,9,21],[36,40],{"name":37,"affiliation":38,"role":39},"Stijn Vanstraelen, MD","Universitaire Ziekenhuizen KU Leuven","PRINCIPAL_INVESTIGATOR",{"name":41,"affiliation":38,"role":39},"Philippe Nafteux, MD, PhD",[43],{"name":37,"role":44,"phone":45,"phoneExt":46,"email":47},"CONTACT","16347863","0032","stijn.vanstraelen@kuleuven.be",[49],{"facility":50,"status":51,"city":52,"state":30,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"University Hospitals Leuven","RECRUITING","Leuven","3000","Belgium","BE",{"type":57,"coordinates":58},"Point",[59,60],4.70093,50.87959,{"lat":60,"lon":59},[63],{"name":37,"role":44,"phone":45,"phoneExt":46,"email":47},{"type":39,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":38,"oldNameTitle":30,"oldOrganization":30},"Stijn Vanstraelen","Principal investigator","100542683","molecular-assessment-for-gastro-esophageal-cancer-100542683",false,"NCT06346054","Molecular Assessment for Gastro-Esophageal Cancer","MAGEC","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any breath or blood analysis\n2. \\>18 years old\n3. Barrett's esophagus or treatment naïve gastro-esophageal cancer stage I to IV\n4. Voluntary healthy controls\n\nExclusion Criteria:\n\n1. \\\u003C18 years old\n2. Patient has history of:\n\n   1. Active other cancer than gastro-esophageal cancer\n   2. Prior cancer treated \\\u003C3 years ago\n   3. Hepatic dysfunction\u002Fliver failure (MELT \\>7)\n3. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the study plan.\n4. Insufficient\u002Funreliable quality of breath (e.g., breath flow) or plasma sample (e.g., haemolytic sample)\n5. Incarcerated individuals",true,"ALL","18 Years","100 Years",{"count":79,"type":80},1000,"ESTIMATED","INTERVENTIONAL",[83],"NA","The goal of this minimally invasive interventional study is to learn if oncometabolic biomarkers, detected in the exhaled breath and blood can identify early-stage gastro-oesophageal cancer in patient at risk for gastro-oesophageal cancer.\n\nThe main questions this study aims to answer:\n\nAre oncometabolites proficient and reproducible enough to function as diagnostic biomarkers? Can these biomarkers identify early-stage gastro-esophageal cancer? Researchers will compare participants with gastro-oesophageal cancer to healthy controls and participants with Barrett's esophagus to detect meaningful differences between the groups.\n\nParticipants will provide a breath and blood sample during their routine standard of care visits.",[86,87,88],"Esophageal Cancer","Gastric Cancer","Barrett Esophagus",[90,91,92,93],"Oncometabolites","Early-stage cancer","Diagnostic testing","Screening","2026-02-14",{"date":96,"type":97},"2026-02-17","ACTUAL",{"date":99,"type":97},"2024-08-01",{"date":101,"type":80},"2029-07-01",{"name":5,"class":6},1]